Replication-competent genome-length HCV RNA and subgenomic HCV replicons. The genomelength genotype 1b HCV RNAs and subgenomic RNA replicons were comprised of the viral 5 nontranslated RNA (NTR), driving expression of the neomycin phosphotransferase gene (neo), followed by the encephalomyocarditis virus IRES and either the complete HCV-N strain open reading frame (ORF) (genome-length RNA) or the Con1 strain NS3-NS5B coding region (subgenomic replicon) and the authentic HCV 3 IUSÃAvtÃ 6ÃUurÃqrvhvÃsÃ!"Ãpryy containing the replicating genome-length HCV-N RNA has been described previously (S1). Two cell lines (A7 and HP) containing replicating subgenomic RNAs were derived from a plasmidtranscribed RNA containing the exact sequence of I 377 NS3-3 ÃS2). This cDNA clone was produced using an oligonucleotide cDNA synthesis strategy as described previously (S3), except that the cDNA included flanking XbaI restriction sites. Proper cDNA clones were identified by DNA sequencing, and the assembled replicon cDNA was subsequently cloned into pACYC184 (New England BioLabs) to yield pACYC HCV 1bpt. The final cDNA construct possessed a T7 promoter at the 5 ÃrvÃsÃurÃC8WÃrrprÃhqÃhÃvrÃScaI restriction site at the HCV 3 terminus, enabling the in vitro production of replicon RNA possessing an authentic HCV 3 terminus. Replicon RNA was transcribed from ScaI-digested plasmid DNA using T7 RNA polymerase. RNA was purified free of DNA and then transfected into Huh7 cells using the TransMessenger reagent and the manufacturer's protocol (Qiagen). Each transfection included 1 x10 6 cells that were plated into a 10 cm culture dish. Forty-eight hrs after transfection the cells were spilt into a 150 mm culture dish, and selection for stable cell populations and clones harboring the HCV replicon RNA was facilitated by the addition of 400 µg/ml G418 to the culture media. After 24 days of selection, surviving cell colonies were picked and individually expanded. We confirmed that the selected cells harbored replicon RNA rather than integrated plasmid cDNA, and we characterized the viral RNA abundance, replication efficiency, viral protein expression, and the growth rates of the resulting replicon cell lines. The complete nucleotide and deduced amino acid sequence of each respective replicon RNA was determined by sequencing the products of RT-PCR reactions carried out as described (S4). By these procedures we isolated and characterized several Huh7 cell populations and clones that contain genetically distinct HCV RNA replicon variants, including the A7 and HP replicon variants. We determined that the HP replicon sequence contains two adaptive mutations in the NS3 coding region (P1115L and K1609E), while the A7 replicon variant contains mutations at different sites within the NS3 coding region (A111P and L1701F). These HCV RNA replicons will be described in greater detail elsewhere.
HCV RNA or subgenomic replicons were cultured in DMEM supplemented with 800 µg/ml or 200 µg/ml G418, respectively. To cure 2-3 cells of the replicating genome-length HCV RNA, cells were cultured for 14 days in the presence of 100 International Units/ml of IFN-α2b, following which HCV RNA and proteins were no longer detectable. Cured cells were designated 2-3c, and lacked selectable G418 resistance.
Tetracycline (tet)-regulated osteosarcoma OS-2 cell lines UHCV11 (S5), UTH28 (S6) , and UNS3-4A-24 (S7) conditionally expressing the complete HCV genotype 1a ORF, core, or NS3-4A coding regions, respectively, were a kind gift from Dr. Darius Moradpour. UTA6 5A 22 osteosarcoma cells conditionally express NS5A from HCV 1b and were a kind gift from Dr. Stephen Polyak. HNS5A 1B-1 cells (S8) were a kind gift from Dr. Michael Katze, and similarly express the HCV NS5A protein-coding region under control of the tet-regulated promoter. HCV protein expression was controlled by culturing cells in the presence or absence of 1 µg/ml tetracycline. For NS3/4A protease inhibition studies, cells were cultured in media containing 2-20 µM SCH6, a member of a recently described class of potent experimental peptidic ketoamide inhibitors of the HCV NS3/4A serine protease that was kindly provided by Drs. Michael Murray, Stephany Bogen and Bruce Malcolm of the Schering-Plough Research Institute, Kenilworth, NJ.
Plasmids and site-directed mutagenesis. Plasmids pISG56-luc, pANTES-luc, pISG15-luc, and pIFN-β luc were kind gifts from Drs. Ganes Sen, John Hiscott, Nancy Reich, and Zhijian Chen, respectively. Plasmids encoding the HCV 1A core-p7 and NS3-4A proteins were generated through PCR amplification of the appropriate coding region from the p90/HCV H77 genotype 1a clone (S9). Protein-coding regions were amplified using the oligonucleotide primer sequences (sense; HCV core) 5 Ã666ÃGAA TTC ATG AGC ACG AAT CCT AAA CCT CAA AG -3 Ãhq 5 Ã666ÃTCT AGA CTA TGC GTA TGC CCG CTG AGG CAA C -3 Ãhvrr0ÃC8WÃpr0 (sense; HCV NS3) 5 ÃTATAATCTTATGGCGCCCATCACGGCGTACGCCCAG 3 ÃhqÃ$ TTTGGATCCTTACGTGACGACCTCCAGGTCGGCCGA 3 ÃhvrrÃC8WÃIT"0Ãrr NS3-4A) 5 ÃTATAATCTTATGGCGCCCATCACGGCGTACGCCCAG 3 ÃhqÃ$ ATAGGATCCTTAGCACTCTTCCATCTCATCGAACTCCTGG 3 ÃhvrrÃIT"#60 (sense NS4A) 5 ÃTTTAAGCTTAGCACCTGGGTGCTCGTTGGCGGCGTCC 3 ÃhqÃ$ ATAGGATCCTTAGCACTCTTCCATCTCATCGAACTCCTGG 3 ÃhvrrÃIT#6ÃUur resulting PCR fragments contained 5 ÃHindIII and a 3 ÃBamH1 restriction sites in addition to an in-frame ATG codon to initiate translation. HCV 1b NS5A and NS3-4A expression constructs were prepared by PCR amplification of the HCV 1b replicon template cDNA using the oligonucleotide primers (sense, NS5A) 5 ÃAAG CTT ATG TCC GGC TCG TGG -3 ÃhqÃ$ TCT AGA CTA GCA GCA GAC GAC GTC CTC ACT AGC -3 ÃhvrrÃIT$6ÃhqÃrr NS3-4A) 5 ÃAAGCTTATGGCGCCTATTACGGCCTAC 3 ÃhqÃ$ TCTAGACTAGCACTCTTCCATCTCATCGAA 3 ÃhvrrÃIT"#6ÃPCR products encoded an in-frame ATG codon and 5 ÃHindIII and 3 ÃXbaI restriction sites, and were cloned into the respective sites of pcDNA3.1(+) (Invitrogen Life Technologies). The NS5B expression construct was generated by subcloning the PvuII/NheI restriction fragment from pBI/GFP/NS5B 1a (a generous gift from Dr. Curt Hagedorn) into the EcoRV/XbaI restriction sites of pcDNA3.1. pNS4AB-His and pNS4B-His were kindly provided by Dr. Karla Kirkegaard. pIRF-3 5D and pIRF-3 ∆N encode the phospho-mimetic, constitutively active IRF-3 and dominant-negative mutants of IRF-3, respectively, and were kindly provided by Dr. John Hiscott (S10).
Protease-deficient (C1125A) and helicase/RNA binding-deficient (W1528A) mutants of the HCV NS3 protein were described previously (S11,S12), and were generated by site-directed mutagenesis of the wild-type pcDNANS3-4A construct using the QuikChange TM XL SiteDirected Mutagenesis Kit (Stratagene) as recommended by the manufacturer. Mutagenic primer sequences (mutation sites are underlined) were (sense) 5 CTTGACACCATGCACCGCCGGCAGCTCGGAC 3 ÃhqÃ$ GTCCGAGCTGCCGGCGGTGCATGGTGTCAAG 3 ÃhvrrÃsÃ8 !$6ÃhqÃrrÃ$ CGCGGGCTGTGCTGCGTACGAGCTCACGC 3 ÃhqÃ$ GCGTGAGCTCGTACGCAGCACAGCCCCGCG 3 ÃhvrrÃsÃX $!'6ÃUurÃ9I6 sequences of all expression constructs were verified by the UT Southwestern Medical Center DNA sequencing core facility.
Transfection and luciferase assay. Transfection of plasmid DNA was carried out with FuGENE 6 transfection reagent (Roche Molecular Biochemicals) as recommended by the manufacturer. For each luciferase reporter experiment we transfected multiple wells of 24-well plates, in which each well contained 4x10 4 cells in 1 ml DMEM. For a particular transfection combination each set of wells was transfected in the presence of DMEM from a transfection master mix containing, on a per well basis, 50 ng of Renilla luciferase reporter plasmid pCMV Renilla-luc (used to monitor transfection efficiency), 100 ng of the indicated IRF-3-dependent promoter-firefly luciferase reporter plasmid, and 0.6 µl FuGENE 6 in a total volume of 20 µl of serum free cell culture media. We used 100 ng of the β-galactosidase reporter plasmid pSV-βgal and the in situ β-gal assay (Promega) to evaluated culture transfection efficiency of our FuGENE transfection protocol. Culture transfection efficiencies for experiments in this report ranged from 70-85% of all cells in a given culture. For Sendai virus infection (described below), transfected cells were cultured for 24 hr at 37 0 C prior to virus infection. For transient expression of HCV proteins or IRF-3, 10 5 cells were transfected in the well of a 6-well culture dish with a similar mixture that contained 0.5 or 1 µg of the indicated expression construct, and transfected cells were cultured a further 48 hr prior to harvesting. For detection of IRF-5D by immunostaining, 250 ng of pIRF-5D were transfected into cells within wells of tissue culture chamber slides, and cells were evaluated for IRF-3 expression 48 hr later. For luciferase assays, the Dual-Luciferase R Reporter Assay System (Promega) was used as recommended by the manufacturer, except that assays were carried out with 20 µl cell lysate and 50 µl of assay reagents. Luciferase activity was measured with a luminometer over a 10 second interval following an initial 2 second delay after the addition of the assay reagent to the cell lysate. All analyses were conducted on cells or cell extracts 24-48 hr after transfection. Statistical analysis of luciferase activity levels was performed using the Student's one-tailed t test with pooled variance.
Sendai virus infection.
Cells were infected with Sendai virus (SenV; Charles River Laboratory) for 16 hrs using an inoculum of 100 hemeagglutinin units/ml culture media as described previously (S13). Sendai virus was prepared at the appropriate dilution in serum-free media from a concentrated virus stock. 0.25 or 1 ml of diluted virus were added to cells in 24 or 6-well plates, respectively, and inoculated cultures were placed at 37 0 C to facilitate virus attachment and infection. After 2 hr an equal volume of pre-warmed DMEM containing 20% FCS was added to each well of the culture dish, and cells were further cultured for an additional 16 hr prior to harvesting. For each experiment, mock-infected control cultures were similarly incubated in the absence of added virus. We conducted immunoblot analyses with Sendai virusspecific antiserum to confirm that HCV proteins did not interfere with Sendai virus infection or replication.
Immunofluorescence analysis. Cells (2-5 × 10 4 ) were plated in tissue culture chamber slides and transfected and/or infected as described above. After an appropriate interval (16 hr for SenV infection or 24-48 hr for transfection), slides were washed with PBS and fixed with 4% paraformaldehyde for 30 min at room temperature. Cell monolayers were permeablized with a solution of PBS/0.2% Triton X-100 for 15 min, followed by a 1 hr incubation in PBS containing 10% normal goat serum. After rinsing with PBS, cells were incubated for 1 hr in the presence of a 1/500 dilution of rabbit polyclonal anti-human IRF-3 antibody in PBS (generously provided by Dr. Michael David), washed three times with PBS/0.5% Tween-20, and incubated for 1 hr with a 1/1000 dilution of goat anti-rabbit IgG-FITC antibody conjugate. Cells were then washed 3 times, allowed to dry, and the slides overlayed with Vectashield solution (Vector Labs), after which cover slips were mounted and sealed. Fluorescence microscopy was carried out as described (S14), or with a Zeiss LSM 510 META confocal microscope in the U.T.M.B. Infectious Disease and Toxicology Optical Imaging core facility.
Immunoblot analysis. For assessment of Sendai virus or HCV protein and actin expression, cells were harvested, extracts prepared, and subjected to immunoblot analysis exactly as described (S14) . For experiments that included analysis of IRF-3 expression and assessment of the hyperphosphorylated (activated) IRF-3 isoform, cells were harvested and lysates produced according to the procedure of Hiscott and colleagues (S13). We included okadeic acid (1 µM) in all extract buffers in order to assure preservation of the phosphorylated isoforms of IRF-3. Proteins (20 µg) were separated by SDS-PAGE. Gels containing 7.5% acrylamide were used for the separation of IRF-3 isoforms. All other immunoblots were carried out following electrophoretic separation of proteins through gels containing 10-15% acrylamide. After electrophoresis, proteins were transferred to NitroPure nitrocellulose transfer membrane (Micron Separations Inc.) and blots were processed for immunodetection of proteins as described (S14). We used the following monoclonal (mAb) or polyclonal (pAb) antibody reagents: anti-Sendai virus pAb (a kind gift from Dr. Ilkka Julkunen), anti-HCV core C7-50 and anti-HCV NS3 1B6 mAbs (kindly provided by Dr. Darius Moradpour), anti-HCV E1 mAb A4 and anti-HCV E2 mAb A1 (kindly provided by Dr. Jean Dubuisson), anti-HCV NS4A mAb (Virogen, Inc., clone 4-F5), anti-HCV NS4B rabbit pAb serum (kindly provided by Dr. Ralf Bartenschlager), anti-HCV NS5B rabbit pAb serum (kindly provided by Dr. Curt Hagedorn), anti-HCV NS5A (human patient serum, kindly provided through informed consent by Dr. William Lee), anti-P56 rabbit pAb serum (kindly provided by Dr. Ganes Sen), anti-ISG15 rabbit pAb serum (kindly provided by Dr. Arthur Haas), goat anti-human actin pAb serum (Santa Cruz) or mouse monoclonal antihuman actin (Sigma), and peroxidase-conjugated secondary donkey anti-rabbit, donkey antimouse, donkey anti-goat or donkey anti-human pAbs (Jackson Immuno Research). Protein bands were visualized using the ECL+ Western Blotting detection reagents (Amersham Biosciences) followed by exposure of the blot to film.
Northern blot analysis. RNA was extracted from cells using Trizol Reagent as recommended by the manufacturer (Invitrogen Life Technologies, Inc.). Purified RNA was resuspended in water, quantified by spectometry, and mixed with RNA loading buffer. After heating at 50°C for 10 min, 10 µg of RNA were separated through a 1% agarose gel containing 2.2 M formaldehyde, 20 mM MOPS (pH 7.0), 8 mM NaOAc and 1 mM EDTA (pH 8.0). To process the gel for transfer of RNA, the gel was soaked in water for 1 hr with gentle agitation followed by incubation in 20× SSC for 15 min. RNA transfer onto Nytran membrane was carried out using the Schleicher & Schuell Turboblotter downward transfer system as recommended by the manufacturer. DNA probes specific for the HCV NS3 coding region or to human glyceraldehyde 3-phosphate dehydrogenase were generated using Klenow DNA polymerase and mixed nonomer random primers in a reaction that contained α 32 P-dCTP. Hybridization reactions were carried out using the ULTRAhyb TM reagent (Ambion) and 10 6 cpm/ml of radiolabeled probe at 42°C for 16 hr. Blots were rinsed twice for 5 min. each with preheated 2× SSC/0.1% SDS wash buffer, followed by two 15 min washes with 0.1× SSC/0.1% SDS wash buffer. Blots were subjected to autoradiography. In some experiments probe hybridization was quantified by phosphorimager analysis.
